Kuboki et al. demonstrated that a high CTC count assessed by CS predicted a decrease in OS in 63 patients with advanced CRC receiving cetuximab in combination with chemotherapy as third-line treatment, but EGFR expression in CTCs did not predict response to cetuximab [195]. This evidence concerns the gene EGFR and colorectal carcinoma.